Skip to main content
Sinocare Inc. logo

Sinocare Inc. — Investor Relations & Filings

Ticker · 300298 ISIN · CNE100001CJ0 LEI · 3003008DEKI00A51LU77 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,250 across all filing types
Latest filing 2021-01-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300298

About Sinocare Inc.

https://www.sinocare.com

Sinocare Inc. specializes in the research, development, and manufacturing of biosensor technology and rapid testing products for chronic disease management. The company is primarily recognized for its blood glucose monitoring systems, including meters and test strips, which serve a global patient base. Its product portfolio extends to point-of-care testing (POCT) solutions for HbA1c, uric acid, blood lipids, and other metabolic indicators. Through the integration of advanced sensing technologies and digital health platforms, Sinocare provides comprehensive diagnostic tools for diabetes and related metabolic disorders. The company focuses on delivering affordable and accurate monitoring solutions to improve the quality of life for individuals with chronic conditions worldwide.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the controlling shareholder of the company. It details the number of shares pledged, the purpose of the pledge, and assurances about the absence of risks related to the pledge. There is no financial statement, earnings data, or management discussion. The document is a regulatory disclosure about share pledging, which fits the category of Regulatory Filings (RNS) as it is a compliance announcement about share pledge status and related risks, not a financial report or capital change announcement.
2021-01-22 Chinese
关于控股股东、实际控制人减持计划期限届满暨实施情况的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the completion of a share reduction plan by the controlling shareholder and actual controller of the company. It details the number of shares reduced, the methods of reduction, dates, and the impact on shareholding percentages. It references relevant securities laws and stock exchange rules. There is no financial data, earnings information, or report content. The document is a formal disclosure of insider share transactions by a director or major shareholder, fitting the definition of Director's Dealing.
2021-01-19 Chinese
关于全资子公司三诺健康管理有限公司参与增资上海医药大健康云商股份有限公司的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the progress of a capital increase investment by a wholly-owned subsidiary of the company into another company. It includes extensive information about the transaction overview, parties involved, investment amounts, payment terms, conditions precedent, and other related contractual details. There is no indication that this is a financial report such as an annual or interim report, nor is it a transcript, audit report, or earnings release. The document is not a simple notification of voting results or a board change. It clearly relates to financing activities, specifically a capital increase and investment transaction. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2021-01-19 Chinese
关于控股股东减持公司可转债的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the reduction of holdings of convertible bonds by the controlling shareholder of the company. It details the issuance of convertible bonds, the shareholder's initial allocation, and the recent sale of these bonds. There is no financial report, earnings data, or management discussion. The document is a formal notification about a transaction involving the company's convertible bonds by a major shareholder. This fits the category of a Major Shareholding Notification (MRQ) because it reports a significant change in ownership levels of convertible bonds by a controlling shareholder.
2021-01-13 Chinese
北京国枫律师事务所关于公司向不特定对象发行可转换公司债券在深圳证券交易所上市的法律意见书
Regulatory Filings
2021-01-08 Chinese
中信证券股份有限公司关于公司向不特定对象发行可转换公司债券之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is a detailed listing sponsorship letter (上市保荐书) issued by a securities company (中信证券股份有限公司) for the issuance of convertible bonds by 三诺生物传感股份有限公司. It includes extensive information about the issuer's business, technology, financial data, risks, and compliance with regulatory requirements. The document is not a financial report like an annual or interim report, nor is it a simple announcement or certification. It is a formal regulatory filing related to a capital market transaction (issuance of convertible bonds) and contains detailed disclosures required by securities regulators. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to the issuance and listing of convertible bonds and includes comprehensive information about the issuer and the transaction.
2021-01-08 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.